A pharmacovigilance study using the Food and Drug Administration’s Adverse Event Reporting System indicated an increased reporting of CV events such as strokes and ischemic heart disease among patients with RA treated with JAKis compared with anti-TNF therapies.15 This evidence concerns the gene TNF and Stroke.